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Acquired angioedema due to C1 inhibitor deficiency (C1INH-AAE) is a rare and potentially fatal syndrome of bradykinin-mediated
angioedema characterized by episodes of angioedema without urticaria. It typically manifests with nonpitting edema of the skin and
edema in the gastrointestinal (GI) tract mucosa or upper airway. Edema of the upper airway and tongue may lead to life-threatening
asphyxiation. C1INH-AAE is typically under-diagnosed because of its rarity and its propensity to mimic more common abdominal
conditions and allergic reactions. In this article, we present the case of a 62-year-old male with a history of recently diagnosed chronic
lymphocytic leukemia (CLL) who presented to our hospital with recurrent abdominal pain, initially suspected to have Clostridium
difficile colitis and diverticulitis. He received a final diagnosis of acquired angioedema due to C1 esterase inhibitor deficiency due to
concomitant symptoms of lip swelling, cutaneous nonpitting edema of his lower extremities, and complement level deficiencies. He
received acute treatment with C1 esterase replacement and icatibant and was maintained on C1 esterase infusions. He also underwent
chemotherapy for his underlying CLL and did not experience further recurrence of his angioedema.

1. Introduction
Acquired angioedema due to C1 esterase inhibitor deficiency
(C1INH-AAE) is a rare and potentially fatal disorder caused
by acquired consumption of C1 esterase inhibitor. Studies
estimate a prevalence rate between 1 in 100,000 and 1 in
500,000 patients, although it may be higher as the condition
is commonly unrecognized [1]. It may manifest with nonpitting edema of the skin, including the skin of the face, lips,
limbs, or genitals, abdominal pain secondary to edema of the
gastrointestinal mucosa, and severe life-threatening edema
of the upper airway and oral mucosa [2].

2. Case Presentation
A 62-year-old male with a two-month history of recurrent
hospital admissions for abdominal pain presented to the

emergency room with colicky, generalized abdominal pain.
He also reported new asymmetric swelling of his upper and
lower lips. He denied associated difficulty swallowing or
breathing. He had no previous history of angioedema, food
allergies, or new medications. He denied any fever, chills,
malaise, trauma, nausea, vomiting, diarrhea, constipation,
hematochezia or melena, weight loss, sick contacts, neurological deficits, or recent travel history. Of note, he had
never taken angiotensin-converting enzyme inhibitors
(ACEi) or angiotensin receptor blocker medications. He was
a former smoker and quit 14 years ago and reported only
occasional alcohol intake. He had no family history of
angioedema. This was the third hospital admission for abdominal pain episodes within six weeks, with prior episodes
spontaneously resolving within a few days.
Six weeks prior to current presentation, a computed
tomography (CT) scan of the abdomen for a prior bout of
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this illness revealed diffuse small bowel thickening with mild
adjacent mesenteric fat stranding and a thickened, nodular
terminal ileum and cecum. He also had a positive Clostridium difficile stool toxin test. He was treated with metronidazole for C. difficile colitis although diarrhea was not
a prominent symptom. Two weeks prior to current presentation, he was admitted for recurrent abdominal pain for
which another CT was performed, and on this one, he was
found to have severe jejunal edema, new proctocolitis, and
several enlarged mesenteric and inguinal lymph nodes. The
lymph nodes were biopsied and found to have CD5-positive
cells consistent with a new diagnosis of chronic lymphocytic
leukemia/small lymphocytic lymphoma (CLL/SLL), later
confirmed by bone marrow biopsy. The patient was again
treated for presumed C. difficile colitis, due to another
positive stool toxin test, this time with oral vancomycin.
He also received a course of amoxicillin-clavulanate as CT
abdomen showed extensive diverticulosis and evidence of
sigmoid colitis, introducing the possibility of diverticulitis.
Evaluation during that admission included esophagogastroduodenoscopy (EGD) and push enteroscopy. Both were
unremarkable except for previously known Barrett’s
esophagus. Interestingly, he also had asymmetric left lower
limb cutaneous swelling and pain during that admission
that had an unrevealing workup including a negative
Doppler ultrasound.
During the current presentation, vital signs were normal
with oxygen saturation at 95% on room air. Physical examination revealed lungs that were clear to auscultation
without stridor. Symmetric upper and lower lip swelling
without hives was noted (Figure 1). The central abdomen was
mildly tender to palpation two inches above the umbilicus
with no guarding or rebound. No edema was noted in the
lower extremities during this current admission. All other
systems examined were normal.

3. Investigations
Complete blood count revealed a white blood count of
4900/μL (normal: 4,800–10,800/μL), hemoglobin of 12.4
(normal: 14–17.5 g/dL), and platelets of 149,000 (normal:
130,000–400,000/μL). Lactic acid, sedimentation rate, C-reactive
protein, lipase, and liver function tests were normal. Considering
the bouts of unexplained bowel edema and swelling lips
without hives, a diagnostic workup for angioedema was pursued. Functional C1 esterase inhibitor level was found to be 4%
(normal: >40%), along with C1 esterase inhibitor antigen of
<3 mg/dl (normal: 21–39 mg/dl), C4 complement < 1.7 mg/dl
(normal: 12–38 mg/dl), and low normal C1q level of 113 μg/ml
(normal: 109–242 μg/ml). C3 complement level was normal at
88.6 mg/dl (normal: 59–152 mg/dl). C. difficile stool toxin test
during this admission was negative. Stool samples were also
negative for Salmonella, Shigella, Escherichia coli, Campylobacter, Yersinia enterocolitica, Giardia, Vibrio, and
Aeromonas. CT abdomen and pelvis (Figure 2) showed
jejunal enteritis with progressive duodenitis and stable
abdominopelvic lymphadenopathy. A repeat C1q level
performed 6 months later was low at <50 μg/ml
(109–242 μg/ml).
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Figure 1: Patient with symmetric lip swelling of upper and lower lips.

4. Differential Diagnosis
Given the patient’s history of positive C. difficile stool tests,
a diagnosis of C. difficile colitis was initially assigned, although repeat stool toxin assay was negative. Diverticulitis,
acute pancreatitis, peptic ulcer disease, acute cholecystitis,
and inflammatory bowel syndrome were excluded based on
clinical history, negative biochemical and stool tests, EGD,
and CT abdomen/pelvis results. Stool studies were negative
for bacterial or parasitic infection that could otherwise
explain the CT scan findings. Viral gastroenteritis was
considered although patient denied any nausea, vomiting, or
diarrhea, and symptoms appeared to be recurrent.
Since nonspecific abdominal pain was accompanied with
symptoms of lip swelling and recent cutaneous swelling in
his lower extremities, a suspicion was formed of angioedema. Allergic angioedema was excluded as the patient
denied urticaria and exposure to precipitating agents and
had abnormal complement levels in his serum. Similarly, the
presence of low C1-INH levels [3] and the absence of ACEi
use excluded ACEi-induced angioedema. Hereditary
angioedema (HAE) was unlikely because our patient denied
a family history of angioedema and experienced onset of
symptoms in his 6th decade, as opposed to before the 2nd
decade which is more typical of HAE [4].

5. Treatment
Patient was urgently administered intravenous methylprednisolone 125 mg and benadryl. Once a diagnosis of acquired
C1 esterase deficiency was made, he received C1 esterase replacement and icatibant (a bradykinin B2 receptor antagonist).
He was subsequently maintained on C1 esterase replacement
therapy and given rescue injections of icatibant for acute
exacerbations. He also received outpatient chemotherapy for
his CLL/SLL with six cycles of rituximab, cyclophosphamide,
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Figure 2: CT abdomen findings before and after treatment. (a) Before treatment, the patient was noted to have jejunal enteritis, which is
indicated by the target sign (red arrow). (b) After treatment, the patient had resolution of jejunitis (blue arrow).

vincristine, and prednisone (R-CVP). He had no further episodes of abdominal pain, lip swelling, or lower extremity
swelling. Interval imaging with CT abdomen showed resolution of jejunitis and duodenitis (Figure 2).

6. Discussion
Approximately half of patients with C1INH-AAE may have
upper airway edema, and consequently death from asphyxiation or anoxic brain injury can occur in up to 30% of
patients [3, 5, 6]. However, more benign and nonspecific
presentations of GI angioedema and cutaneous edema may be
the only manifesting symptoms. GI symptoms of angioedema
include nonspecific colicky abdominal pain, vomiting, diarrhea, and abdominal distension [2], which can be mistaken
for common abdominal conditions such as gastroenteritis and
diverticulitis. Cutaneous edema may manifest as nonpitting
edema of the skin, usually affecting the face but may also
involve the lower extremities, mimicking allergic reactions
and thrombophlebitis.
Because the diagnosis is extremely uncommon and its
symptoms are protean, there is frequently a delay in diagnosis.
A retrospective nationwide study in France found a median
delay in diagnosis of 10 months [3], whereas a national audit in
the United Kingdom showed a diagnostic delay of 5 years [7].
Our patient was diagnosed within only 2 months of symptom
onset, but after three hospital admissions and incorrect diagnoses of C. difficile colitis and diverticulitis.
The key pathologic abnormality in C1INH-AAE is the
acquired deficiency of C1-inhibitor enzyme (C1-INH). A
major function of C1-INH is the inhibition of kallikrein, which
is a protease that cleaves kininogen and releases bradykinin [8].
Consequently, in C1-INH deficiency, the absence of inhibition
of kallikrein leads to increased bradykinin levels, which then
facilitate vasodilation and increased tissue permeability,
resulting in angioedema flares [8]. C1-INH deficiency in
acquired angioedema (AAE) may be caused by excessive
consumption due to hyperactivation of the classic complement
pathways associated with underlying lymphoproliferative

diseases or by autoantibodies (autoimmune mediated).
Both lymphoproliferative disorders and autoantibodies
frequently coexist in the same patients and one may lead to
the other [9–11]. Our patient did not have antibodies tested,
but he did have CLL (a lymphoproliferative disease).
Laboratory findings include low C1-INH activity, low C3
and C4 levels, and autoantibodies to C1-INH in up to 70% of
patients with AAE [12, 13]. C1q level is typically low in up to
70% of patients, although it may be normal in early stages of the
disease [14]. Our patient had low C1-INH activity, low C1-INH
level, low C4 complement, and an initially low-normal level of
C1q but low repeat C1q levels six months after diagnosis.
Most patients afflicted with C1INH-AAE also have
concomitant lymphoproliferative and autoimmune disorders [15]. In one review that included 136 cases of acquired
C1 inhibitor deficiency, lymphatic malignancies were
identified in 35%, MGUS in 32%, autoimmune diseases in
8%, with adenocarcinoma, and other malignancies identified
in 6% [15]. Lymphoproliferative disorders and B-cell malignancies are the most commonly associated conditions
[10, 16], especially splenic marginal zone lymphomas [17].
Associated autoimmune disorders include systemic lupus
erythematosus, cryoglobulinemia, and autoimmune hemolytic anemia [18, 19]. Interestingly, there have also been
reports of association with Helicobacter pylori [20]. In our
case, the patient had been recently diagnosed with CLL,
a non-Hodgkin’s lymphoma with known association with
C1INH-AAE [13, 21–23].
Primary pharmacologic treatment for acute C1INHAAE includes C1 esterase inhibitor concentrate from human plasma or recombinant C1 inhibitor concentrate,
icatibant (a synthetic bradykinin B2 receptor antagonist),
and/or ecallantide (a kallikrein inhibitor). The most widely
used therapy is C1 esterase inhibitor concentrate, although
resistance to this treatment over time, necessitating higher
doses to control symptoms, has been reported [10].
Importantly, unlike more common causes of angioedema including allergic and drug-induced angioedema,
acute presentations of C1INH-AAE typically do not respond
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to corticosteroids, antihistamine, or epinephrine [24].
Prophylactic treatment to prevent recurrent symptoms of
C1INH-AAE includes C1 esterase inhibitor concentrate administered every 3-4 days, attenuated androgens (i.e., danazol
and stanozolol) and antifibrinolytic agents [17, 25]. Our index
patient received C1 esterase inhibitor concentrate and icatibant
twice weekly prophylaxis with C1 esterase inhibitor concentrate. He experienced resolution of his symptoms following
initiation of that therapy and treatment of his lymphoma with
chemotherapy. Other case reports have documented similar
improvement in angioedema symptoms following treatment
of lymphoma [26].
Physicians caring for patients with unexplained abdominal pain especially with concomitant skin, lip, or airway
swelling should consider angioedema as a possibility and
should check laboratory testing for confirmation.

7. Teaching Points
(1) Wider appreciation of the possibility of C1INH-AAE
in refractory recurrent abdominal pain, particularly
in patients with lymphoproliferative disorders, could
lead to proper and timely medical therapy and avert
fatal respiratory complications from laryngeal and
upper airway edema.
(2) Abdominal symptoms in C1INH-AAE may mimic
gastroenteritis and diverticulitis, whereas nonpitting
cutaneous edema may be mistaken for allergic reactions and thrombophlebitis.
(3) Unlike more common causes of angioedema including
allergic and drug-induced angioedema, acute presentations of angioedema secondary to C1 esterase
deficiency typically do not respond to corticosteroids,
antihistamine, or epinephrine and necessitate treatment with C1 inhibitor replacement therapy, icatibant, ecallantide, or fresh frozen plasma.
(4) If an underlying associated disease is identified in
a patient with C1INH-AAE, including lymphoproliferative malignancy or autoimmune disease, treatment
of the underlying disease may lead to symptomatic
improvement of C1INH-AAE.
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